Evidence map›Paper›PMID 40235545›Full record

ArticleFrontiers in pharmacology2025

Icarisid Ⅱ modulates mitochondrial dynamics for anti-HBV activity.

Zhengyun Liu, Haiyan Yang, Juan Wen, Dongyan Xiao, Wan Yu, Guo Luo, Qihai Gong, Huan Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhengyun LiuKey Laboratory of Infectious Disease and Biosafety, Provincial Department of Education, Zunyi Medical University, Zunyi, Guizhou, China.
Haiyan YangKey Laboratory of Infectious Disease and Biosafety, Provincial Department of Education, Zunyi Medical University, Zunyi, Guizhou, China.
Juan WenKey Laboratory of Infectious Disease and Biosafety, Provincial Department of Education, Zunyi Medical University, Zunyi, Guizhou, China.
Dongyan XiaoKey Laboratory of Infectious Disease and Biosafety, Provincial Department of Education, Zunyi Medical University, Zunyi, Guizhou, China.
Wan YuKey Laboratory of Infectious Disease and Biosafety, Provincial Department of Education, Zunyi Medical University, Zunyi, Guizhou, China.
Guo LuoKey Laboratory of Infectious Disease and Biosafety, Provincial Department of Education, Zunyi Medical University, Zunyi, Guizhou, China.
Qihai GongKey Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China.
Huan WangKey Laboratory of Infectious Disease and Biosafety, Provincial Department of Education, Zunyi Medical University, Zunyi, Guizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: To investigate the potential anti-hepatitis B virus (HBV) activity of Icariside Ⅱ (ICS Ⅱ), and elucidate its underlying mitochondrial dynamics mechanisms. Methods: The study employed Results: The study found that ICS Ⅱ exhibited significant anti-HBV effects both Conclusion: ICS Ⅱ exhibits significant anti-HBV potential through its regulation of mitochondrial dynamics and ROS production.

Indexed as

hepatitis B virusHepG2.2.15 cellicariside IImitochondrial dynamicreactive oxygen speciesROS

Identifiers

PMID40235545
PMCPMC11996814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.